GDF15 and metabolic syndrome: Importantly, a novel pharmacological agent aimed to target the GFRAL (high-affinity binding receptor for GDF-15/RET (receptor tyrosine kinase) pathway is currently under development for the therapeutic management of obesity and metabolic syndrome, which may have the ability to mitigate cardiovascular risk in patients with metabolic diseases by enhancing the underlying effects of GDF-15 [99].